Ongoing Phase 2b Study in Parkinson’s Disease

A Multicenter, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (KARMET).

We are currently conducting a randomized, placebo-controlled trial in up to 150 patients with Parkinson’s Disease (PD). As of March 2021, we have randomized approximately 110 patients and we expect that results will be available by the end of H1 2021. In a top-line data cut conducted after the first 60+ patients, we confirmed improvement in neurologic symptoms, including hallucinations, dementia, and motor symptoms in-line with previous findings. Based on the strength of these data, we plan to conduct further studies in patients with PD psychosis and PD dementia/NMS. Participating sites include Albany, Hershey, Sarasota, Boca Raton, Pasadena, Port Charlotte, Washington DC, and others. We would like to thank everyone involved for their support on this important trial.

For further information, please go to ClinicalTrials.gov or contact us at KARMETinfo@enterininc.com.